46 completed, 9 terminated, 3 unknown, 2 active not recruiting. 62 Phase 2, 20 Phase 1, 1 Phase 3.
Follow Recurrent Grade 3 Follicular Lymphoma: new trials by email Literature Review of Recurrent Grade 3 Follicular Lymphoma trials Research Report on Recurrent Grade 3 Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2014-05-27 | 2025-06-24 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma alisertib, rituximab, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 14 | 2013-05-21 | 2018-06-06 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma Ibrutinib, Laboratory Biomarker Analysis - Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2013-04-02 | 2026-09-11 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Filgrastim, Genetically Engineered Lymphocyte Therapy - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 8 | 2011-10-20 | 2026-09-11 |
| Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma Ofatumumab, Bortezomib - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | OHSU Knight Cancer Institute | 3 | 2011-10-01 | 2014-07-30 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
Showing 20 of 62. Sign in to see all of them.
Lymphoma, Follicular (62) · Lymphoma, Mantle-Cell (52) · Lymphoma, Large B-Cell, Diffuse (51) · Leukemia, Lymphocytic, Chronic, B-Cell (49) · Lymphoma, B-Cell, Marginal Zone (49) · Lymphoma, Non-Hodgkin (42) · Waldenstrom Macroglobulinemia (39) · Burkitt Lymphoma (37) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (35) · Lymphoma, Large-Cell, Immunoblastic (34) · Hodgkin Disease (29) · Mycosis Fungoides (29) · Sezary Syndrome (29) · Lymphoma, Large-Cell, Anaplastic (28) · Lymphoma, T-Cell, Cutaneous (27)
Hemic and Lymphatic Diseases (62) · Immune System Diseases (62) · Immunoproliferative Disorders (62) · Lymphatic Diseases (62) · Lymphoma (62) · Lymphoproliferative Disorders (62) · Neoplasms by Histologic Type (62) · Neoplasms (61) · Lymphoma, B-Cell (55) · Hematologic Diseases (52) · Leukemia (51) · Leukemia, Lymphoid (51) · Chronic Disease (49) · Disease Attributes (49) · Leukemia, B-Cell (49)
Rituximab (18) · Peripheral Blood Stem Cell Transplantation (13) · fludarabine phosphate (13) · Mycophenolic Acid (12) · Whole-Body Irradiation (12) · Cyclophosphamide (10) · Cyclosporine (9) · Tacrolimus (9) · Etoposide (7) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5) · Methotrexate (5) · Busulfan (4) · Flow Cytometry (4) · Lenalidomide (4)
National Cancer Institute (NCI) (18) · Fred Hutchinson Cancer Center (15) · Mayo Clinic (6) · Chinese PLA General Hospital (3) · University of Washington (3) · Case Comprehensive Cancer Center (2) · City of Hope Medical Center (2) · Ohio State University Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (2) · M.D. Anderson Cancer Center (1) · Medical College of Wisconsin (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine (1) · University of Chicago (1)
United States (57) · Italy (5) · China (4) · Germany (2) · Canada (1) · Denmark (1) · Singapore (1)
Ajay Gopal (4) · Brenda Sandmaier (4) · David Maloney (3) · Sonali Smith (3) · Anas Younes (2) · John Gerecitano (2) · Thomas Witzig (2) · Adam Petrich, MD (1) · Barbara Pro (1) · Brenda Cooper (1) · Brenda Cooper, MD (1) · Craig Okada (1) · Craig Reeder, M.D. (1) · David Grinblatt (1) · Elizabeth L Budde, MD,PhD (1)
PMID 32499241, PMID 34515338, PMID 19900571, PMID 20837940, PMID 21073974, PMID 21300924, PMID 21508413, PMID 21725056, PMID 24241210, PMID 25085357, PMID 25444722, PMID 26213141, PMID 26764356, PMID 27118452, PMID 28314788, PMID 28424162, PMID 29074501, PMID 29263894, PMID 30454872, PMID 31481800, PMID 32245502, PMID 32430507, PMID 39161543, PMID 41804087
P30CA015704 (9), P30CA015083 (5), N01CM62202 (4), P01CA018029 (4), N01CM62201 (3), P01CA078902 (3), N01CM17003 (2), P30CA008748 (2), P30CA014599 (2), P30CA033572 (2), P50CA097274 (2), U01CA062502 (2), N01CM00032 (1), N01CM00039 (1), N01CM00070 (1)